Yahoo · Oct 9, 2026
Don't Bet the Outcome, Own the Platform with DICE
Tema's Paisley Nardini breaks down DICE, the first prediction markets ETF, with exposure to Kalshi, Polymarket, Coinbase, and Robinhood on this episode of Behind the Ticker.
DI
NASDAQ · DICE
DICE Therapeutics, Inc.
Healthcare · Biotechnology
$21.85
Up+$0.03 (+0.06%)
Updated Nov 4, 2026, 11:03 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.27B
- P/E ratio
- -22.94
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 149
- Avg. volume
- 1.91M
Price performance · DICE
DICE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
DICE closed at $21.85 after 21 trading sessions, down 10.40% for the selected period.
- Last close
- $21.85
- Period change
- -10.40%
- Period low
- $21.55
- Period high
- $24.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $21.79 | $21.8472 | $21.79 | $21.8472 | 149 |
| Nov 2, 2026 | $21.5514 | $21.5514 | $21.5514 | $21.5514 | 139.38 |
| Oct 30, 2026 | $22.64 | $22.64 | $21.49 | $21.5451 | 2.13K |
| Oct 29, 2026 | $22.4792 | $22.4792 | $22.4792 | $22.4792 | 19 |
| Oct 28, 2026 | $22.25 | $22.4843 | $22.25 | $22.4843 | 1.15K |
| Oct 27, 2026 | $22.415 | $22.415 | $22.36 | $22.393 | 3.36K |
| Oct 26, 2026 | $22.50 | $22.51 | $22.18 | $22.2533 | 1.19K |
| Oct 23, 2026 | $24.81 | $24.81 | $22.6818 | $22.6818 | 946.85 |
| Oct 22, 2026 | $23.00 | $23.00 | $22.95 | $22.9707 | 393 |
| Oct 21, 2026 | $23.12 | $23.285 | $23.12 | $23.2582 | 950.95 |
| Oct 20, 2026 | $22.80 | $23.18 | $22.80 | $22.9943 | 1.76K |
| Oct 19, 2026 | $23.15 | $23.1501 | $22.7986 | $22.7986 | 965.1 |
| Oct 16, 2026 | $23.73 | $23.73 | $23.1331 | $23.1331 | 2.21K |
| Oct 15, 2026 | $22.99 | $23.7197 | $22.99 | $23.7197 | 509 |
| Oct 14, 2026 | $23.55 | $23.55 | $23.02 | $23.1351 | 4.07K |
| Oct 13, 2026 | $23.92 | $23.92 | $23.8691 | $23.8691 | 475.08 |
| Oct 12, 2026 | $24.71 | $24.71 | $23.95 | $23.9515 | 2.07K |
| Oct 9, 2026 | $23.93 | $24.28 | $23.9199 | $24.28 | 1.37K |
| Oct 8, 2026 | $23.55 | $23.7021 | $23.55 | $23.7021 | 1.72K |
| Oct 7, 2026 | $23.6601 | $23.82 | $23.66 | $23.7852 | 1.93K |
| Oct 6, 2026 | $24.59 | $24.59 | $24.3834 | $24.3834 | 1.75K |
Latest DICE news
The latest Smart Investors Daily articles mentioning DICE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
DICE research
Overview
Company profile and research snapshot.
Company profile
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $60.00
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 9, 2023 | HC Wainwright & Co. | Neutral | — |
| Jun 26, 2023 | Needham | Hold | — |
| Jun 21, 2023 | Canaccord Genuity | Hold | — |
| Jun 21, 2023 | HC Wainwright & Co. | Neutral | — |
| Jun 20, 2023 | Canaccord Genuity | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 9, 2026
U.S. Prediction Market Trades Are Predominantly Sports-Based
The S&P Global Market Intelligence Kagan US third quarter 2026 Consumer Insights survey asked respondents about their use of prediction market platforms. Read more here.
Yahoo · Oct 8, 2026
Want Private-Market Access to Kalshi and Polymarket? Try This ETF
The Tema Trading & Prediction Markets ETF (DICE) offers pre-IPO exposure to Kalshi and Polymarket, plus holdings like Robinhood, Coinbase and Interactive Brokers, amid industry growth forecasts.
Benzinga · Sep 23, 2026
Anthropic, Kalshi and Polymarket Before Their IPOs? ETFs Are Finding a Way in
Tema ETFs is offering pre-IPO exposure to Anthropic, Kalshi and Polymarket through ETFs, using SPVs to access private-market names.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
